A new study (HERO) published in the Journal of Hepatology has investigated the association between direct-acting antiviral treatment adherence and sustained virological response (SVR) in patients with hepatitis C virus (HCV) infection and who inject drugs. Over a 12-week treatment period, electronic blister packs assessed adherence to sofosbuvir with velpatasvir in people who inject drugs (n = 623 individuals initiated direct-acting antiviral treatment). Overall SVR rate was 92.7%, with a median adherence of 75%. Higher adherence was associated with SVR. Interruption of treatment and early discontinuation were associated with lower SVR; in particular, patients who discontinued treatment in the first month, or had ≥2 weeks of treatment interruption, had low SVR. The researchers also observed that SVR >90% is achievable even with adherence of 50%.

发表在《肝病学杂志》上的一项新研究 (HERO)调查了丙型肝炎病毒 (HCV) 感染和注射吸毒患者的直接抗病毒治疗依从性与持续病毒学应答 (SVR) 之间的关系。在 12 周的治疗期内，电子泡罩包装评估了注射吸毒者对索磷布韦和维帕他韦的依从性（n  = 623 人开始直接抗病毒治疗）。总体 SVR 率为 92.7%，中位依从性为 75%。更高的依从性与 SVR 相关。治疗中断和提前停药与较低的 SVR 相关；特别是，在第一个月内停止治疗或治疗中断≥2周的患者的SVR较低。研究人员还观察到，即使依从性为 50%，SVR 也可以达到 >90%。